STAA
STAAR Surgical Company (NASDAQ)
Healthcare — Medical Instruments & Supplies
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Price History
Fundamentals
| Market Cap | $1.41B |
| P/E Ratio (TTM) | - |
| Forward P/E | 28.72 |
| EPS (TTM) | $-0.42 |
| Dividend Yield | - |
| Profit Margin | -7.24% |
| Revenue Growth | 119.60% |
| ROE | -5.99% |
| Debt/Equity | 10.58 |
| Recommendation | None |
| Analyst Target | $29.67 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 46.8 |
| Beta | 1.23 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $35.87 |
| 52-Week Low | $15.59 |
| 50-Day Avg | $28.93 |
| 200-Day Avg | $24.45 |
| Avg Volume | 966.3K |
| Volume | 5.7K |
Performance Analysis
NEUTRALSTAA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:32 UTC
Back to Screener Export Report